Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The safety, tolerability, and antileukemic response of ziftomenib in combination with
standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will
be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will
be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Not Available
I
Fedorov, Kateryna
NCT06001788
VICC-DTHEM23484P
Expanded Access Protocol for Product which does not conform to the TECELRA (Afamitresgene autoleucel, suspension for intravenous infusion) Commercial Release Specification.
Sarcoma
Sarcoma
Sarcoma
N/A
Keedy, Vicki
NCT06617572
VICCSAR24510
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Lymphoma
Lymphoma
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus
standard of care (SOC) in first-line therapy in participants with high-risk large B-cell
lymphoma.
standard of care (SOC) in first-line therapy in participants with high-risk large B-cell
lymphoma.
Lymphoma
III
Jallouk, Andrew
NCT05605899
VICCCTT2298